On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating on Ocera Therapeutics, Inc. (NASDAQ: OCRX)

Company: Ocera Therapeutics, Inc. (OCRX)
Category: Analyst Alerts

Following Ocera Therapeutics, Inc.’s (NASDAQ: OCRX) Key Opinion Leader (KOL) conference call on hepatic encephalopathy and other complications of liver disease, Aegis Capital reiterated its ‘Buy’ rating and price target of $3 on shares of the company’s stock. The analyst noted the importance of OCR-002’s potential to reduce hospital stays by 1.5 days and believes that, combined with the IV formulation, the prospective savings for the hospitals could encourage them to adopt OCR-002 when available. Additionally, the company also recently initiated the dosing phase of its phase 1/2a trial of oral OCR-002 in cirrhosis. The end of phase 2 meeting for IV OCR-002 is expected in the third quarter of 2017, and data for the oral OCR-002 phase 2a study in cirrhotic patients is expected by year end.

For more information, visit www.ocerainc.com

About Ocera

Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. Ocera’s HE clinical development efforts also include a recently completed phase 2b clinical trial, STOP-HE, which evaluated the safety and efficacy of intravenously-administered (IV) OCR-002 in resolving neurocognitive symptoms of acute HE in hospitalized patients with elevated ammonia. The company is preparing to meet with the FDA later this year to review the IV OCR-002 program and discuss potential development paths forward.

About NetworkNewsBreaks

NetworkNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217